{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:54:51Z","timestamp":1788317691836,"version":"build-2803163510"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Euan Macdonald Centre"},{"name":"Motor Neuron Disease Research and the Anne Rowling Regenerative Neurology Clinic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>People with motor neuron disease often experience non-motor symptoms that may occur secondary to, or distinct from, motor degeneration and that may significantly reduce quality of life, despite being under-recognized and evaluated in clinical practice. Non-motor symptoms explored in this population-based study include pain, fatigue, gastrointestinal issues, poor sleep, low mood, anxiety, problematic saliva, apathy, emotional lability, cognitive complaints and sexual dysfunction. People registered on the Clinical Audit Research and Evaluation of motor neuron disease platform, the Scottish Motor Neuron Disease Register, were invited to complete a questionnaire on non-motor symptoms and a self-reported Amyotrophic Lateral Sclerosis Functional Rating Scale. The questionnaire comprised a pre-defined list of 11 potential non-motor symptoms, with the opportunity to list additional symptoms. A total of 120 individuals participated in this cross-sectional study, a 39% response rate of those sent questionnaires (n = 311); 99% of participants recruited (n = 120) experienced at least one non-motor symptom, with 72% (n = 120) reporting five or more. The symptoms most often reported were pain and fatigue (reported by 76% of participants, respectively). The symptoms reported to be most impactful were gastrointestinal issues (reported as \u2018severe\u2019 by 54% of participants who experienced them), followed by pain and problematic saliva (51%, respectively). Lower Amyotrophic Lateral Sclerosis Functional Rating Scale scores, indicating more advanced disease and being a long survivor [diagnosed over 8 years ago; Black et al. (Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. Neurobiol Aging. 2017;51:178.e11-178.e20.)], were significantly associated with reporting more symptoms; 73% of respondents were satisfied with the frequency that non-motor symptoms were discussed in clinical care; 80% of participants indicated they believe evaluation of non-motor symptom is important to include as outcomes in trials, independent of their personal experience of these symptoms. The preferred method of assessment was completing questionnaires, at home. The overwhelming majority of people with motor neuron disease report non-motor symptoms and these frequently co-occur. Pain, fatigue, gastrointestinal issues, sleep, mood, anxiety, problematic saliva, apathy, emotional lability, cognitive complaints and sexual dysfunction are prevalent. People with motor neuron disease who had worse physical function and those who were long survivors were more likely to report more symptoms. Where reported, these symptoms are frequent, impactful and a priority for people with motor neuron disease in clinical care and trial design.<\/jats:p>","DOI":"10.1093\/braincomms\/fcad336","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T14:42:13Z","timestamp":1701787333000},"source":"Crossref","is-referenced-by-count":16,"title":["Non-motor symptoms in motor neuron disease: prevalence, assessment and impact"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9843-0778","authenticated-orcid":false,"given":"Emily","family":"Beswick","sequence":"first","affiliation":[{"name":"Centre for Clinical Brain Sciences, the University of Edinburgh , Edinburgh , UK"},{"name":"Anne Rowling Regenerative Neurology Clinic, the University of Edinburgh , Edinburgh , UK"},{"name":"Euan MacDonald Centre for MND Research, the University of Edinburgh , Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2584-0236","authenticated-orcid":false,"given":"Deborah","family":"Forbes","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, the University of Edinburgh , Edinburgh , UK"},{"name":"Anne Rowling Regenerative Neurology Clinic, the University of Edinburgh , Edinburgh , UK"},{"name":"Euan MacDonald Centre for MND Research, the University of Edinburgh , Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheala","family":"Johnson","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, the University of Edinburgh , Edinburgh , UK"},{"name":"Anne Rowling Regenerative Neurology Clinic, the University of Edinburgh , Edinburgh , UK"},{"name":"Euan MacDonald Centre for MND Research, the University of Edinburgh , Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Newton","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, the University of Edinburgh , Edinburgh , UK"},{"name":"Anne Rowling Regenerative Neurology Clinic, the University of Edinburgh , Edinburgh , UK"},{"name":"Euan MacDonald Centre for MND Research, the University of Edinburgh , Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3697-8516","authenticated-orcid":false,"given":"Rachel","family":"Dakin","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, the University of Edinburgh , Edinburgh , UK"},{"name":"Anne Rowling Regenerative Neurology Clinic, the University of Edinburgh , Edinburgh , UK"},{"name":"Euan MacDonald Centre for MND Research, the University of Edinburgh , Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Glasmcher","sequence":"additional","affiliation":[{"name":"Anne Rowling Regenerative Neurology Clinic, the University of Edinburgh , Edinburgh , UK"},{"name":"Euan MacDonald Centre for MND Research, the University of Edinburgh , Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Abrahams","sequence":"additional","affiliation":[{"name":"Euan MacDonald Centre for MND Research, the University of Edinburgh , Edinburgh , UK"},{"name":"Human Cognitive Neurosciences, Psychology, School of Philosophy, Psychology and Language Sciences, the University of Edinburgh , Edinburgh, EH16 4SB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Carson","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, the University of Edinburgh , Edinburgh , UK"},{"name":"Anne Rowling Regenerative Neurology Clinic, the University of Edinburgh , Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharthan","family":"Chandran","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, the University of Edinburgh , Edinburgh , UK"},{"name":"Anne Rowling Regenerative Neurology Clinic, the University of Edinburgh , Edinburgh , UK"},{"name":"Euan MacDonald Centre for MND Research, the University of Edinburgh , Edinburgh , UK"},{"name":"UK Dementia Research Institute, the University of Edinburgh , Edinburgh, EH16 4SB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4276-639X","authenticated-orcid":false,"given":"Suvankar","family":"Pal","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, the University of Edinburgh , Edinburgh , UK"},{"name":"Anne Rowling Regenerative Neurology Clinic, the University of Edinburgh , Edinburgh , UK"},{"name":"Euan MacDonald Centre for MND Research, the University of Edinburgh , Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"2024022919593777600_fcad336-B1","doi-asserted-by":"crossref","first-page":"178.e11","DOI":"10.1016\/j.neurobiolaging.2016.12.013","article-title":"Genetic epidemiology of motor neuron disease-associated variants in the Scottish population","volume":"51","author":"Black","year":"2017","journal-title":"Neurobiol Aging"},{"key":"2024022919593777600_fcad336-B2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3389\/fnins.2019.00951","article-title":"Cognitive, emotional and psychological manifestations in amyotrophic lateral sclerosis at baseline and overtime: A review","volume":"13","author":"Benbrika","year":"2019","journal-title":"Front Neurosci"},{"key":"2024022919593777600_fcad336-B3","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/bs.irn.2017.04.009","article-title":"Nonmotor symptoms in amyotrophic lateral sclerosis: A systematic review","volume":"134","author":"Fang","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"2024022919593777600_fcad336-B4","doi-asserted-by":"crossref","DOI":"10.1080\/21678421.2023.2220748","article-title":"Non-motor symptoms in amyotrophic lateral sclerosis: Lessons from Parkinson\u2019s disease","author":"Shojaie","year":"2023","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2024022919593777600_fcad336-B5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fneur.2016.00117","article-title":"Non-motor symptoms in patients suffering from motor neuron diseases","volume":"7","author":"G\u00fcnther","year":"2016","journal-title":"Front Neurol"},{"issue":"4","key":"2024022919593777600_fcad336-B6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1468-1331.2011.03540.x","article-title":"Pain in amyotrophic lateral sclerosis: A population-based controlled study","volume":"19","author":"Chi\u00f2","year":"2012","journal-title":"Eur J Neurol"},{"issue":"4","key":"2024022919593777600_fcad336-B7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3233\/JND-210632","article-title":"Non-motor symptoms of amyotrophic lateral sclerosis: A multi-faceted disorder","volume":"8","author":"Nash","year":"2021","journal-title":"J Neuromuscular Dis"},{"key":"2024022919593777600_fcad336-B8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3389\/fneur.2018.01005","article-title":"Clinical and radiological markers of extra-motor deficits in amyotrophic lateral sclerosis","volume":"9","author":"Christidi","year":"2018","journal-title":"Front Neurol"},{"issue":"3","key":"2024022919593777600_fcad336-B9","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s11682-020-00359-7","article-title":"Neuroanatomical associations of the Edinburgh Cognitive and Behavioural ALS screen (ECAS)","volume":"15","author":"Chenji","year":"2021","journal-title":"Brain Imaging Behav"},{"issue":"3\u20134","key":"2024022919593777600_fcad336-B10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/21678421.2015.1131831","article-title":"Patient-reported problematic symptoms in an ALS treatment trial","volume":"17","author":"Raheja","year":"2016","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"2024022919593777600_fcad336-B11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archneur.1996.00550020045014","article-title":"The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis","volume":"53","author":"The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group","year":"1996","journal-title":"Arch Neurol"},{"issue":"3","key":"2024022919593777600_fcad336-B12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/mus.20900","article-title":"Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: Efficacy and factors associated with pain relief","volume":"37","author":"McClelland","year":"2008","journal-title":"Muscle Nerve"},{"issue":"1","key":"2024022919593777600_fcad336-B13","first-page":"CD004030","article-title":"Enteral tube feeding for amyotrophic lateral sclerosis\/motor neuron disease","volume":"2011","author":"Katzberg","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1\u20132","key":"2024022919593777600_fcad336-B14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/21678421.2020.1812661","article-title":"Motor neuron disease register for England, Wales and Northern Ireland\u2014An analysis of incidence in England","volume":"22","author":"Opie-Martin","year":"2021","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"2024022919593777600_fcad336-B15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/jnnp-2019-321737","article-title":"Relationship between neuropsychiatric disorders and cognitive and behavioural change in MND","volume":"91","author":"McHutchison","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024022919593777600_fcad336-B16","doi-asserted-by":"crossref","first-page":"743688","DOI":"10.3389\/fneur.2021.743688","article-title":"Factors that influence non-motor impairment across the ALS-FTD spectrum: Impact of phenotype, sex, age, onset and disease stage","volume":"12","author":"Devenney","year":"2021","journal-title":"Front Neurol"},{"issue":"5\u20136","key":"2024022919593777600_fcad336-B17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/21678421.2019.1615951","article-title":"The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis\/motor neuron disease","volume":"20","author":"Young","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"2024022919593777600_fcad336-B18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12955-016-0507-6","article-title":"Associations between psychological factors and health-related quality of life and global quality of life in patients with ALS: A systematic review","volume":"14","author":"van Groenestijn","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"2024022919593777600_fcad336-B19"},{"issue":"12","key":"2024022919593777600_fcad336-B20","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/14737175.2021.1984883","article-title":"Developments in the assessment of non-motor disease progression in amyotrophic lateral sclerosis","volume":"21","author":"Chi\u00f2","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"2024022919593777600_fcad336-B21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00415-019-09615-3","article-title":"Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis\/motor neuron disease? A national study reconciling previous conflicting literature","volume":"267","author":"Edge","year":"2020","journal-title":"J Neurol"},{"issue":"12","key":"2024022919593777600_fcad336-B22","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1080\/09638288.2020.1846797","article-title":"Flexibility to manage and enhance quality of life among people with motor neurone disease","volume":"44","author":"Ando","year":"2013","journal-title":"Disabil Rehabil"},{"issue":"3","key":"2024022919593777600_fcad336-B23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: Diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol"},{"issue":"1","key":"2024022919593777600_fcad336-B24","first-page":"CD011776","article-title":"Symptomatic treatments for amyotrophic lateral sclerosis\/motor neuron disease","volume":"1","author":"Ng","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"2024022919593777600_fcad336-B25","doi-asserted-by":"crossref","first-page":"e1610","DOI":"10.1212\/WNL.0000000000007242","article-title":"Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials","volume":"92","author":"Van Den Berg","year":"2019","journal-title":"Neurology"},{"key":"2024022919593777600_fcad336-B26","author":"European Medicines Agency"},{"issue":"5","key":"2024022919593777600_fcad336-B27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/WCO.0000000000000861","article-title":"Current trends in the clinical trial landscape for amyotrophic lateral sclerosis","volume":"33","author":"van Eijk","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"2024022919593777600_fcad336-B28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40263-021-00820-1","article-title":"Pathophysiology and treatment of non-motor dysfunction in amyotrophic lateral sclerosis","volume":"35","author":"Mahoney","year":"2021","journal-title":"CNS Drugs"},{"issue":"12)","key":"2024022919593777600_fcad336-B29","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1007\/s00415-020-10203-z","article-title":"A systematic review of non-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis","volume":"268","author":"Beswick","year":"2021","journal-title":"J Neurol"},{"issue":"12","key":"2024022919593777600_fcad336-B30","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1007\/s00415-020-10203-z","article-title":"A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis","volume":"268","author":"Beswick","year":"2020","journal-title":"J Neurol"},{"issue":"3\u20134","key":"2024022919593777600_fcad336-B31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/21678421.2019.1582673","article-title":"Clinical audit research and evaluation of motor neuron disease (CARE-MND): A national electronic platform for prospective, longitudinal monitoring of MND in Scotland","volume":"20","author":"Leighton","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1\u20132","key":"2024022919593777600_fcad336-B32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"J Neurol Sci"},{"issue":"1","key":"2024022919593777600_fcad336-B33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/jnnp-2019-321138","article-title":"Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R","volume":"91","author":"Bakker","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3\u20134","key":"2024022919593777600_fcad336-B34","first-page":"175","article-title":"Remote digital assessment of amyotrophic lateral sclerosis functional rating scale\u2013a multicenter observational study","volume":"24","author":"Meyer","year":"2022","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"8","key":"2024022919593777600_fcad336-B35","doi-asserted-by":"crossref","first-page":"e802","DOI":"10.1212\/WNL.0000000000008869","article-title":"ALS phenotype is influenced by age, sex, and genetics: A population-based study","volume":"94","author":"Chi\u00f2","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"2024022919593777600_fcad336-B36","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00415-019-09190-7","article-title":"Changing epidemiology of motor neurone disease in Scotland","volume":"266","author":"Leighton","year":"2019","journal-title":"J Neurol"},{"issue":"5\u20136","key":"2024022919593777600_fcad336-B37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/21678421.2019.1612435","article-title":"Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010\u20132015","volume":"20","author":"Raymond","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"4","key":"2024022919593777600_fcad336-B38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/jnnp-2011-300480","article-title":"Non-invasive ventilation in motor neuron disease: An update of current UK practice","volume":"83","author":"O'Neill","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"2024022919593777600_fcad336-B39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/archneur.64.2.232","article-title":"Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: Examination of symptoms and signs at disease onset and during follow-up","volume":"64","author":"Tartaglia","year":"2007","journal-title":"Arch Neurol"},{"issue":"3","key":"2024022919593777600_fcad336-B40","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00415-022-11505-0","article-title":"Genotype\u2013phenotype characterisation of long survivors with motor neuron disease in Scotland","volume":"270","author":"Leighton","year":"2023","journal-title":"J Neurol"},{"issue":"4","key":"2024022919593777600_fcad336-B41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/17482968.2011.556744","article-title":"Prevalence of major depression in ALS: Comparison of a semi-structured interview and four self-report measures","volume":"12","author":"Ferentinos","year":"2011","journal-title":"Amyotroph Lateral Scler"},{"issue":"5\u20136","key":"2024022919593777600_fcad336-B42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/21678421.2012.751614","article-title":"Prevalence and characteristics of pain in early and late stages of ALS","volume":"14","author":"Rivera","year":"2013","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"7\u20138","key":"2024022919593777600_fcad336-B43","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3109\/21678421.2014.951944","article-title":"The evaluation of pain in amyotrophic lateral sclerosis: A case controlled observational study","volume":"15","author":"Wallace","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"10047","key":"2024022919593777600_fcad336-B44","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(16)00737-6","article-title":"The frontotemporal dementia-motor neuron disease continuum","volume":"388","author":"Burrell","year":"2016","journal-title":"Lancet"},{"issue":"3\u20134","key":"2024022919593777600_fcad336-B45","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3109\/21678421.2015.1030430","article-title":"Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders","volume":"16","author":"Niven","year":"2015","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1\u20132","key":"2024022919593777600_fcad336-B46","first-page":"92","article-title":"The clinical impact of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) and neuropsychological intervention in routine ALS care","volume":"21","author":"Hodgins","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"11","key":"2024022919593777600_fcad336-B47","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1007\/s00415-022-11273-x","article-title":"Patient perspectives on digital healthcare technology in care and clinical trials for motor neuron disease: An international survey","volume":"269","author":"Helleman","year":"2022","journal-title":"J Neurol"},{"issue":"1","key":"2024022919593777600_fcad336-B48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.2006.104828","article-title":"Descriptive epidemiology of amyotrophic lateral sclerosis: New evidence and unsolved issues","volume":"79","author":"Logroscino","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024022919593777600_fcad336-B49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/NSS.S183504","article-title":"Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives","volume":"11","author":"Boentert","year":"2019","journal-title":"Nat Sci Sleep"},{"issue":"3","key":"2024022919593777600_fcad336-B50","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0006-3223(98)00011-0","article-title":"The prevalence of depressive disorders in the United Kingdom","volume":"45","author":"Ohayon","year":"1999","journal-title":"Biol Psychiatry"},{"issue":"9","key":"2024022919593777600_fcad336-B51","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe","volume":"21","author":"Wittchen","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5-6","key":"2024022919593777600_fcad336-B52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/17482960802566824","article-title":"Prognostic factors in ALS: a critical review","volume":"10","author":"Chio","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"issue":"10","key":"2024022919593777600_fcad336-B53","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1468-1331.2010.03016.x","article-title":"Neurobehavioral symptoms in ALS are negatively related to caregivers\u2019 burden and quality of life","volume":"17","author":"Chi\u00f2","year":"2010","journal-title":"Europ Jou Neurol"},{"issue":"2","key":"2024022919593777600_fcad336-B54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/17482960701642437","article-title":"Behaviour in amyotrophic lateral sclerosis","volume":"9","author":"Gibbons","year":"2008","journal-title":"Amyotrop Lateral Scler"},{"issue":"6","key":"2024022919593777600_fcad336-B55","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/jnnp-2015-310772","article-title":"Multidimensional apathy in ALS: validation of the Dimensional Apathy Scale","volume":"87","author":"Radakovic","year":"2016","journal-title":"Jou Neurol. Neurosurg Psychiatry"},{"key":"2024022919593777600_fcad336-B56","article-title":"The prevalence and management of saliva problems in motor neuron disease: A 4-year analysis of the Scottish MND Register","author":"Pearson","year":"2021","journal-title":"Neurodegener Dis"},{"key":"2024022919593777600_fcad336-B57","first-page":"19","article-title":"Sialorrhea in patients with ALS: current treatment options","volume":"9","author":"Garuti","year":"2019","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"1","key":"2024022919593777600_fcad336-B58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/146608299300079484","article-title":"Gastrointestinal dysfunction in amyotrophic lateral sclerosis","volume":"1","author":"Toepfer","year":"2000","journal-title":"Amyotrop Lateral Scler Other Motor Neuron Disord"},{"issue":"5","key":"2024022919593777600_fcad336-B59","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2018.23","article-title":"Physiological changes in neurodegeneration-mechanistic insights and clinical utility","volume":"14","author":"Ahmed","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"2024022919593777600_fcad336-B60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00415-004-0351-1","article-title":"Sexuality in patients with amyotrophic lateral sclerosis and their partners","volume":"251","author":"Wasner","year":"2004","journal-title":"Jou Neurol"},{"issue":"6","key":"2024022919593777600_fcad336-B61","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/jnnp-2018-319684","article-title":"Sexuality and intimacy in ALS: systematic literature review and future perspectives","volume":"90","author":"Poletti","year":"2019","journal-title":"Jou Neurol Neurosurg Psychiatry"},{"key":"2024022919593777600_fcad336-B62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archneur.1996.00550020045014","article-title":"Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group","volume":"53","author":"The Amyotrophic Lateral Sclerosis Functional Rating Scale","year":"1996","journal-title":"Arch Neurol"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcad336\/54092496\/fcad336.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/6\/1\/fcad336\/56688568\/fcad336.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/6\/1\/fcad336\/56688568\/fcad336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T03:12:51Z","timestamp":1730776371000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcad336\/7462153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcad336","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2023,12,7]]},"article-number":"fcad336"}}